Skip to main content

Advertisement

SpringerLink
Log in

Urodynamic Effects of Once-Daily Tadalafil in Men with LUTS Secondary to Clinical BPH

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Lower urinary tract symptoms (LUTS) are common and increase with age in men with benign prostatic hypertrophy (BPH). Erectile dysfunction (ED) also increases with age and is often a comorbid condition with BPH. Treatment with phosphodiesterase type 5 (PDE5) inhibitors aimed at decreasing breakdown of nitric oxide (NO) is a mainstay of treatment for ED. Because NO has been found to mediate male prostatic and urinary function in multiple ways, there is increasing interest in PDE5 inhibitors addressing concomitant LUTS. Several studies have shown significant improvement in LUTS after treatment with PDE5 inhibitors; however, concern exists that PDE5 inhibitors exert their beneficial effects through impairment of bladder function. Because limited invasive urodynamic data exist to address these queries, tadalafil’s impact on bladder function was recently evaluated. Results indicate that tadalafil treatment had no negative impact on bladder function, as measured by detrusor pressure at maximum flow or any other urodynamic parameter assessed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Berry SJ, Coffey DS, Walsh PC, et al.: The development of benign prostatic hyperplasia with age. J Urol 1984, 132:474–479.

    CAS  PubMed  Google Scholar 

  2. Garraway WM, Collins GN, Lee RJ: High prevalence of benign prostatic hypertrophy in the community. Lancet 1991, 338:469–471.

    Article  CAS  PubMed  Google Scholar 

  3. Baine WB, Yu W, Summe JP, et al.: Epidemiologic trends in the evaluation and treatment of lower urinary tract symptoms in elderly male Medicare patients from 1991 to 1995. J Urol 1998, 160:816–820.

    Article  CAS  PubMed  Google Scholar 

  4. Roehrborn CG, McConnell JD, Barry MJ, et al.: Guidelines on the Management of Benign Prostatic Hyperplasia. Linthicum, MD: American Urological Association, Education and Research, Inc; 2003.

  5. Sciarra A: Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies. Eur Urol 2007, 51:1485–1487.

    Article  CAS  PubMed  Google Scholar 

  6. • Mouli S, McVary KT: PDE5 inhibitors for LUTS. Prostate Cancer Prostatic Dis 2009, 12:316–324. This is a detailed review of proposed mechanisms of action of PDE5 inhibitors for LUTS.

  7. • Dmochowski R, Roehrborn C, Klise S, et al.: Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo-controlled 12-week clinical trial. J Urol 2010, 183:1092–1097. This is an initial urodynamic study revealing no negative impact on bladder function after treatment with tadalafil.

  8. Feldman H, Goldstein I, Hatzichristou D, et al.: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994, 151:54–61.

    CAS  PubMed  Google Scholar 

  9. Rosen RC, Giuliano F, Carson CC: Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005, 47:824–837.

    Article  PubMed  Google Scholar 

  10. Rosen R, Altwein J, Boyle P, et al.: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003, 44:637–649.

    Article  PubMed  Google Scholar 

  11. Rajfer J, Aronson WJ, Bush PA, et al.: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992, 326:90–94.

    Article  CAS  PubMed  Google Scholar 

  12. Andersson KE: Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol 2003, 170:S6–S14.

    Article  PubMed  Google Scholar 

  13. Carvajal JA, Germain AM, Huidobro-Toro JP, Weiner CP: Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol 2000, 184:409–420.

    Article  CAS  PubMed  Google Scholar 

  14. Corbin JD: Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res 2004, 16:S4–S7.

    Article  CAS  PubMed  Google Scholar 

  15. Andersson KE: Pharmacology of lower urinary tract smooth muscle and penile erectile tissues. Pharmacol Rev 1993, 45:253–308.

    Google Scholar 

  16. Smet PJ, Jonavicius J, Marshall VR, de Vente J: Distribution of nitric oxide synthase-immunoreactive nerves and identification of the cellular targets of nitric oxide in guinea-pig and human urinary bladder by cGMP immunohistochemistry. Neuroscience 1996, 71:337–348.

    Article  CAS  PubMed  Google Scholar 

  17. Gillespie JI, Markerink-van Ittersum M, de Vente J: Expression of neuronal nitric oxide synthase (nNOS) and nitric-oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder. Cell Tissue Res 2005, 321:341–351.

    Article  CAS  PubMed  Google Scholar 

  18. Hedlund P, Ekstrom P, Larsson B, et al.: Heme oxygenase and NO synthase in the human prostate-relation to adrenergic, cholinergic and peptide containing nerves. J Auton Nerv Syst 1997, 63:115–126.

    Article  CAS  PubMed  Google Scholar 

  19. Waldkirch E, Ückert S, Langnäse K, et al.: Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol 2007, 52:495–502.

    Article  CAS  PubMed  Google Scholar 

  20. Bloch W, Klotz T, Loch C, et al.: Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997, 33:1–8.

    Article  CAS  PubMed  Google Scholar 

  21. Klotz T, Mathers MJ, Bloch W, et al.: Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 1999, 31:335–341.

    Article  CAS  PubMed  Google Scholar 

  22. Tinel H, Stelte-Ludwig B, Hütter J, Sandner P: Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006, 98:1259–1263

    Article  CAS  PubMed  Google Scholar 

  23. Filippi S, Morelli A, Sandner P, et al.: Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007, 148:1019–1029.

    Article  CAS  PubMed  Google Scholar 

  24. Uckert S, Kuthe A, Jonas U, Stief CG: Characterization and functional reference of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001, 166:2484–2490.

    Article  CAS  PubMed  Google Scholar 

  25. Uckert S, Hedlund P, Oelke M, et al.: Immunohistochemical presence of phosphodiesterase 11A in the human prostate. J Urol 2004, 171:352.

    Google Scholar 

  26. Ückert S, Hedlund P, Andersson KE, et al.: Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future? Eur Urol 2006, 50:1194–1207.

    Article  PubMed  CAS  Google Scholar 

  27. Lindberg C, Nishtman D, Malmqvist UP, et al.: Increased expression of RhoA in prostates of spontaneously hypertensive rats. J Urol 2004, 171(Suppl):348, A1320.

    Google Scholar 

  28. Bing W, Chang S, Hypolite JA, et al.: Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol 2003, 285:F990–F997.

    PubMed  Google Scholar 

  29. Chang S, Hypolite JA, Zderic SA, et al.: Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase. Am J Physiol Regul Integr Comp Physiol 2005, 289:R1124–R1130.

    CAS  PubMed  Google Scholar 

  30. Chang S, Hypolite JA, Changolkar A, et al.: Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int J Impot Res 2003, 15:53–62.

    Article  CAS  PubMed  Google Scholar 

  31. Seko T, Ito M, Kureishi Y, et al: Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res 2003, 92:411–418.

    Article  CAS  PubMed  Google Scholar 

  32. Rees RW, Foxwell NA, Ralph DJ, et al.: Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 2003, 170:2517–2522.

    Article  CAS  PubMed  Google Scholar 

  33. Rajasekaran M, White S, Baquir A, Wilkes N: Rho-kinase inhibition improves erectile function in aging male Brown Norway rats. J Androl 2005, 26:182–188.

    CAS  PubMed  Google Scholar 

  34. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005, 365:1415–1428.

    Article  CAS  PubMed  Google Scholar 

  35. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D: Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998, 1:157–162.

    Article  PubMed  Google Scholar 

  36. Hammarsten J, Hogstedt B: Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999, 8:29–36.

    Article  CAS  PubMed  Google Scholar 

  37. McVary KT, Razzaq A, Lee C, et al.: Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994, 51:99–107.

    Article  CAS  PubMed  Google Scholar 

  38. Rahman NU, Phonsombat S, Bochinski D, et al.: An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidemic rat. BJU Int 2007, 100:658–663.

    Article  PubMed  Google Scholar 

  39. Hale TM, Okabe H, Bushfield TL, et al.: Recovery of erectile function after brief aggressive anti-hypertensive therapy. J Urol 2002, 168:348–354.

    Article  CAS  PubMed  Google Scholar 

  40. McVary KT, Rademaker A, Lloyd GL, Gann P: Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005, 174:1327–1333.

    Article  PubMed  Google Scholar 

  41. Tarcan T, Azadzoi KM, Siroky MB, et al.: Age related erectile and voiding dysfunction: the role of arterial insufficiency. Brit J Urol 1998, 82:26–33.

    PubMed  Google Scholar 

  42. Ponholzer A, Temml C, Wehrberger C, et al.: The association between LUTS and vascular risk factors in both sexes. Eur Urol 2006, 50:581–586.

    Article  PubMed  Google Scholar 

  43. Azadzoi KM, Tarcan T, Siroky MB, Krane RJ: Atherosclerosis-induced chronic ischemia causes bladder fibrosis and noncompliance in the rabbit. J Urol 1999, 161:1626–1635.

    Article  CAS  PubMed  Google Scholar 

  44. Azadzoi KM, Babayan RK, Kozlowski R, Siroky MB: Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol 2003, 170:659–663.

    Article  PubMed  Google Scholar 

  45. McVary KT, Roehrborn CG, Kaminetsky JC, et al.: Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007, 177:1401–1407.

    Article  CAS  PubMed  Google Scholar 

  46. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L: Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008, 180:1228–1234.

    Article  CAS  PubMed  Google Scholar 

  47. McVary KT, Monnig W, Camps JL Jr, et al.: Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007, 177:1071–1077.

    Article  CAS  PubMed  Google Scholar 

  48. Stief CG, Porst H, Neuser D, et al.: A randomised, placebo-controlled study to assess the efficacy of twice-daily Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008, 53:1236–1244.

    Article  CAS  PubMed  Google Scholar 

  49. Kaplan SA, Gonzales RR, Te AE: Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007, 51:1717–1723.

    Article  CAS  PubMed  Google Scholar 

  50. Gacci M, Del Popolo G, Macchiarella A, et al.: Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007, 178:2040–2043.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

Dr. Roger Dmochowski is a consultant for Astellas Pharma, Allergan, Medtronic, and Pfizer. No further potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Urologic Surgery, Vanderbilt University Medical Center, A-1302, Medical Center North, Nashville, TN, 37232, USA

    Alex Gomelsky

  2. Louisiana State University Health Sciences Center—Shreveport, 1501 Kings Highway, Shreveport, LA, 71130, USA

    Roger R. Dmochowski

Authors
  1. Alex Gomelsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger R. Dmochowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger R. Dmochowski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gomelsky, A., Dmochowski, R.R. Urodynamic Effects of Once-Daily Tadalafil in Men with LUTS Secondary to Clinical BPH. Curr Urol Rep 11, 254–260 (2010). https://doi.org/10.1007/s11934-010-0122-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-010-0122-8

Keywords

Search

Navigation